Key words: Rheumatoid arthritis, ankylosing spondylitis, treatment, NSAIDs, biologics

نویسندگان

  • Benjamin Franklin
  • Jürgen Braun
  • Joachim Sieper
چکیده

1Rheumazentrum Ruhrgebiet, Herne, Germany; 2Department of Rheumatology, Charité, Campus Benjamin Franklin, Berlin, Germany. Jürgen Braun, MD, Professor Joachim Sieper, MD, Professor Please address correspondence to: Prof. Joachim Sieper, Department of Rheumatology, Charité – Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany E-mail: [email protected] Received and accepted on July 29, 2009. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S146-S147. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2009.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

Tuberculosis (TB) still represents an important issue for public health in underdeveloped countries, but the use of antitumor necrosis factor agents (anti-TNF) for the treatment of inflammatory rheumatic disorders has reopened the problem also in countries with low TB incidence, due to the increased risk of TB reactivation in subjects with latent tuberculosis infection (LTBI). Over the last 5 y...

متن کامل

Clinical use of biologics in vasculitis syndromes

Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent advances in immunosuppressant therapy have radically changed the course of these diseases. However, the standard therapy is not always well tolerated by patients, and some cases are refractory to treatment. New therapeutic possibilities have emerged with the use ...

متن کامل

Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs.

Ankylosing spondylitis (AS) is a chronic inflammatory disease with a prevalence of 0.1–1.2%, and it normally starts in the third decade of life. In contrast to other inflammatory rheumatic diseases, such as rheumatoid arthritis (RA), the therapeutic options are limited and confined to nonsteroidal antiinflammatory drugs (NSAIDs) and, if this treatment fails, to tumor necrosis factor (TNF) block...

متن کامل

Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study

BACKGROUND The relative cost of biologics in the treatment of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a key consideration for managed care payers. OBJECTIVES Our objective was to estimate biologic costs and treatment patterns in US managed care patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/o...

متن کامل

Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs

BACKGROUND Patients with osteoarthritis (OA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs), sometimes with a concomitant gastroprotective proton pump inhibitor (PPI). The present study examines real-life patient adherence to PPIs when coprescribed with NSAIDs. METHODS This retrospective medical record survey ...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006